Encorafenib (LGX818) is a potent and selective oral inhibitor of the BRAF V600E mutation, with an IC50 of 0.3 nM. It is widely used in preclinical oncology research, demonstrating significant antitumor activity in both in vitro cellular assays and in vivo models of melanoma and colorectal cancer.